Biophysics in kinase drug discovery: FBS to PROTAC® ternary complex characterization

Critical Importance of Early Safety Screening in Drug Development

Biophysics in kinase drug discovery: FBS to PROTAC® ternary complex characterisation

Recent Trends in Kinase Drug Discovery

SH2 Domains as a Target Class in Cancer and Inflammation

Pharmacology Discovery Services - Capabilities Video

Comprehensive Identification of Cardiovascular Safety Liabilities Using a Totality of Evidence

Accelerating hit finding programs: Echo MS and RapidFire-MS key advantages

Identify & Characterize New, Potent & Selective Ligands with E3scan Ligand-Binding Assay Technology

Successful Hit Finding for PIM3 Kinase Inhibitors: From HTS to Extended Hit Characterization

Versatile Hit-Finding Strategies for Successful Drug Discovery Programs

Eurofins Discovery Lowers Barriers to Innovation in Research & Development Through Collaboration

Predicting Human Toxicities: A BioMAP® Platform Narrated Case Study

Find your Next Novel Kinase Inhibitor with the KINOMEscan Technology

Decoding Cancer and Inflammation: Identifying Selective Inhibitors of SH2 Domains

Comprehensive In Vitro Approach to Evaluating Transporter-mediated Drug Interactions

Leveraging the E3scanTM technology platform for next-generation targeted protein degradation

Drug Discovery Trends & New Insights from Phenotypic Approaches

Eurofins Discovery IDD Highlights

An efficient and effective PIM3 kinase

In vitro NASH Panels and in vivo NASH models for NASH drug discovery

Komabiotech Webinar - In Vivo Pharmacology and PK Services - Pharmacology Discovery Services (PDS)

Eurofins Discovery Safety Pharmacology Portfolio

Eurofins Discovery: We Know What It Takes

Eurofins Discovery: The Essence of our Entrepreneurial Spirit